This article is more than 5 years old. Information may no longer be current.

IOP decrease seen with standalone iStent procedure

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

A study showed a single iStent trabecular micro-bypass stent significantly reduced IOP in pseudophakic eyes with open-angle glaucoma in a standalone procedure, according to a Glaukos press release.

The retrospective, consecutive case series included 42 pseudophakic eyes with a preoperative mean IOP of 20.26 mm Hg. At 2 years postop, mean medicated IOP in 21 eyes decreased by 6.64 mm Hg, or 33%, to 13.62 mm Hg.

In patients with preoperative medicated IOP of 19 mm Hg or greater, 96% saw an IOP reduction at their last follow-up.

The iStent was approved by the FDA in June 2012 for use with cataract surgery to reduce IOP, and this trial investigated its use as a standalone procedure.

“In this series of iStent procedures occurring between October 2012 and May 2015, we recorded IOP reductions at 1 and 2 years postoperatively that were both clinically and statistically significant,” study investigator John Berdahl, MD, said in the release.